XPro1595, an investigational therapy by INmune Bio, can lower brain inflammation in people with mild to moderate Alzheimer’s disease, according to interim results of a clinical trial. Specifically, the Phase 1b clinical trial (NCT03943264) shows evidence that XPro1595 decreases white matter free water, a biomarker…
Testing of a second and higher dose of ACI-35.030, a potential Alzheimer’s vaccine, is now beginning in a Phase 1b/2a clinical trial, AC Immune announced. Positive interim safety, tolerability, and specificity results from an initial dosing group of patients allowed the trial to advance to its medium…
Vaccines against the flu and pneumonia are associated with a lower risk of developing Alzheimer’s disease, while infections are generally linked to increased mortality among people with dementia, according to three research studies presented at this year’s Alzheimer’s Association International Conference, which is being held virtually this…
AlzeCure Pharma announced positive results from its first clinical study of ACD856 for the potential treatment of Alzheimer’s disease. According to the company, ACD856 showed a good pharmacokinetic profile — namely a significantly shorter human half-life than its predecessor, ACD855 — and suitability for further clinical development as…
Amylyx Pharmaceuticals announced it has completed enrollment for the Phase 2 clinical trial of AMX0035 for treating Alzheimer’s disease. The placebo-controlled trial, PEGASUS (NCT03533257), will evaluate the compound’s safety and tolerability among patients with late mild cognitive impairment or early dementia due to Alzheimer’s disease. Other study…
Experiments on the International Space Station showed gravity affects the formation of amyloids, the pathological tangles of proteins found in the brains of those with Alzheimer’s disease. Both the speed by which they formed and the structure they took in microgravity differed from amyloids formed through similar means in…
A new biosensor using neatly aligned carbon nanotubes may bring scientists one step closer to a blood test for the early detection of Alzheimer’s disease. The nanotubes were able to measure microscopic concentrations of Alzheimer’s main protein biomarkers in blood plasma, and reportedly distinguished Alzheimer’s patients from healthy…
Throughout 2019, Alzheimer’s News Today delivered daily coverage of emerging research, key findings, treatment developments, and clinical trials related to Alzheimer’s disease. We look forward to bringing the same quality of coverage to those living with Alzheimer’s in the coming year. Here are the 10 most-read stories of 2019,…
A recent Phase 1 clinical study of a potential Alzheimer’s therapy showed positive results regarding both safety and biomarkers for cognitive processes. The data support advancing the investigational compound, NDX-1017, developed by Athira Pharma, to later-stage clinical trials. The results, “Phase 1 Study of NDX-1017: Safety, Pharmacokinetics…
Get regular updates to your inbox.